MarketInOut Stock Screener Log In | Sign Up
 

Arbutus Biopharma Corp

IEX • Healthcare • Biotechnology • Quote as of 09/21/2026 13:55
Arbutus Biopharma Corp stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization992.51 mln
Float133 mln
Earnings Date11/11/2026

EPS

0.79
Decent

P / E

6.36
Undervalued

Piotroski F-Score

5 / 9
Neutral

1-Year Forecast

5.46
Modest upside

Relative Strength

44 / 100
Slightly lagging

Debt / Equity

0.01
Debt-free

Business Description

Arbutus Biopharma is a clinical-stage company based in Warminster, Pennsylvania, focused on developing new treatments for chronic Hepatitis B. Its two lead drugs work in different ways ? one reduces harmful viral proteins in the body, while the other helps the immune system fight the infection more effectively. The company also holds a licensing agreement with Alnylam Pharmaceuticals to use their drug delivery technology in its products.

Key Fundamentals

EPS0.79
P/E6.36
ROE101
RPS0.94
ROIC204
ROA90.37
Interest Cover1,940
EBITDA, mln153
EV / EBITDA5.96
EV / EBIT5.96
Revenue, mln182
EV / Revenue5.02

Quote Details

Last 5.03
Change 0.02 (0.4%)
Open 5.03
Volume 1,156,720
Turnover 5,818,302
Average Volume 4,454,392

Financial Ratios

Pre-Tax Profit Margin84
Leverage Ratio1.06
Current Ratio81.42
Price / Book3.87
Price / Tangible Book3.87
Debt / Equity0.01
Price / Sales5.45
PEG Ratio0.28

Financial Strength

Altman Z-Score36.89
Piotroski F-Score 5 / 9
Price to Graham Number1.06
1-Year Target Price5.46
Short Ratio5.03
Short % of Float14.19

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -1.95% 28 / 100   
1 Month 5.45% 87 / 100   
2 Months 18.08% 88 / 100   
6 Months 18.63% 70 / 100   
1 Year 13.8% 60 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us